SI2753334T1 - Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjev - Google Patents
Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjevInfo
- Publication number
- SI2753334T1 SI2753334T1 SI201232012T SI201232012T SI2753334T1 SI 2753334 T1 SI2753334 T1 SI 2753334T1 SI 201232012 T SI201232012 T SI 201232012T SI 201232012 T SI201232012 T SI 201232012T SI 2753334 T1 SI2753334 T1 SI 2753334T1
- Authority
- SI
- Slovenia
- Prior art keywords
- fap
- solid tumors
- proteasome inhibitors
- treating solid
- activated proteasome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161528824P | 2011-08-30 | 2011-08-30 | |
EP12827686.2A EP2753334B1 (en) | 2011-08-30 | 2012-08-30 | Fap-activated proteasome inhibitors for treating solid tumors |
PCT/US2012/053140 WO2013033396A2 (en) | 2011-08-30 | 2012-08-30 | Fap-activated proteasome inhibitors for treating solid tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2753334T1 true SI2753334T1 (sl) | 2023-01-31 |
Family
ID=47757170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201232012T SI2753334T1 (sl) | 2011-08-30 | 2012-08-30 | Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjev |
Country Status (14)
Country | Link |
---|---|
US (5) | US9597410B2 (sl) |
EP (2) | EP2753334B1 (sl) |
JP (2) | JP6207509B2 (sl) |
CN (2) | CN103945856A (sl) |
AU (2) | AU2012301810B2 (sl) |
CA (1) | CA2846852C (sl) |
DK (1) | DK2753334T3 (sl) |
ES (1) | ES2929179T3 (sl) |
HR (1) | HRP20221320T1 (sl) |
HU (1) | HUE060305T2 (sl) |
PL (1) | PL2753334T3 (sl) |
PT (1) | PT2753334T (sl) |
SI (1) | SI2753334T1 (sl) |
WO (1) | WO2013033396A2 (sl) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2753334B1 (en) * | 2011-08-30 | 2022-10-19 | Trustees Of Tufts College | Fap-activated proteasome inhibitors for treating solid tumors |
US20150299143A1 (en) * | 2012-12-03 | 2015-10-22 | F. Hoffmann-La Roche Ag | Substituted triazole and imidazole compounds |
EP3008212A4 (en) * | 2013-06-10 | 2017-05-24 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
WO2015076359A1 (ja) * | 2013-11-21 | 2015-05-28 | 国立大学法人北海道大学 | プロテアソーム阻害性化合物 |
US9737556B2 (en) | 2014-06-13 | 2017-08-22 | Trustees Of Tufts College | FAP-activated therapeutic agents, and uses related thereto |
CN113967258A (zh) * | 2014-06-13 | 2022-01-25 | 塔夫茨大学信托人 | Fap激活的治疗剂以及其相关用途 |
EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
WO2016011088A2 (en) * | 2014-07-14 | 2016-01-21 | Centrax International, Inc. | Epoxyketone compounds for enzyme inhibition |
CN104231047B (zh) * | 2014-08-22 | 2017-06-16 | 亚飞(上海)生物医药科技有限公司 | 水溶性靶向激活的紫杉醇衍生物及其制备和用途 |
EP3184540A4 (en) | 2014-08-22 | 2018-03-21 | Yafei Shanghai Biolog Medicine Science& Technology | Specifically activated micromolecular target coupling body in tumor microenvironment and use thereof |
WO2016210054A1 (en) * | 2015-06-23 | 2016-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Novel rhodol fluorophores for near-infrared imaging |
CN106588965A (zh) | 2015-10-15 | 2017-04-26 | 北京大学 | 脲拟肽硼酸化合物及其药物组合物、制备方法和用途 |
CN105938123B (zh) * | 2015-12-18 | 2018-09-14 | 重庆两江药物研发中心有限公司 | 一种卡非佐米中间体中杂质的检测方法 |
US10590084B2 (en) | 2016-03-09 | 2020-03-17 | Blade Therapeutics, Inc. | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof |
WO2017222915A1 (en) | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Heterocyclic prolinamide derivatives |
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
AU2017292646A1 (en) | 2016-07-05 | 2019-02-07 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
EP3523294A4 (en) | 2016-09-28 | 2021-01-13 | Blade Therapeutics, Inc. | CALPAIN MODULATORS AND THEIR THERAPEUTIC USES |
JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質(fap)標的イメージングおよび治療 |
US11613785B2 (en) | 2017-01-09 | 2023-03-28 | Onkosxcel Therapeutics, Llc | Predictive and diagnostic methods for prostate cancer |
WO2018187418A1 (en) * | 2017-04-04 | 2018-10-11 | Genentech, Inc. | Substrates recognized by fibroblast activation protein (fap) and methods of using the same |
KR102005030B1 (ko) * | 2017-10-31 | 2019-07-29 | 충북대학교 산학협력단 | 프로테아좀 억제제를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물 |
CN108191957B (zh) * | 2017-12-30 | 2021-05-04 | 浙江大学 | 三肽大环衍生物及其制备方法和应用 |
US20210106522A1 (en) | 2018-01-29 | 2021-04-15 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
IL276594B2 (en) * | 2018-02-06 | 2023-11-01 | Univ Heidelberg | FAP inhibitors |
TWI810344B (zh) | 2018-08-02 | 2023-08-01 | 大陸商正大天晴藥業集團股份有限公司 | 氮雜環丁烷衍生物的硼酸酯 |
EP3833374A4 (en) | 2018-08-06 | 2022-04-27 | University Of Kentucky Research Foundation | PROTEASOME INHIBITORS |
GB201820320D0 (en) * | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for FAPalpha |
WO2021072212A1 (en) * | 2019-10-11 | 2021-04-15 | Mayo Foundation For Medical Education And Research | Proteasome inhibitors |
CN111235221B (zh) * | 2020-01-22 | 2022-08-05 | 北京大学第一医院 | 一种fap抑制剂的活性检测方法 |
CZ309380B6 (cs) | 2020-03-30 | 2022-10-26 | Ústav organické chemie a biochemie AV ČR v. v. i | Sloučeniny pro inhibici fibroblastového aktivačního proteinu |
CA3183172A1 (en) * | 2020-06-17 | 2021-12-23 | University Of Utah Research Foundation | Biomarker based patient selection for proteasome inhibitor treatment |
WO2022133288A1 (en) * | 2020-12-17 | 2022-06-23 | Trustees Of Tufts College | Fap-activated radiotheranostics, and uses related thereto |
IL303655A (en) | 2020-12-17 | 2023-08-01 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
ZA86746B (en) | 1985-02-04 | 1986-09-24 | Merrell Dow Pharma | Novel peptidase inhibitors |
US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
WO1995025223A1 (en) | 1994-03-11 | 1995-09-21 | Wilson Greatbatch Ltd. | Low power electromagnetic pump |
US5580979A (en) | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6180402B1 (en) | 1996-11-20 | 2001-01-30 | Qlt Inc. | Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor |
ES2285785T3 (es) | 1997-09-29 | 2007-11-16 | Point Therapeutics, Inc. | Estimulacion de celulas hematopoyeticas in vitro. |
AU766219B2 (en) | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
KR20010052302A (ko) | 1998-05-04 | 2001-06-25 | 바바라 피. 월너 | 조혈 자극 |
ES2189423T3 (es) | 1998-06-05 | 2003-07-01 | Point Therapeutics Inc | Compuestos ciclicos de boroprolina. |
US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
US6285178B1 (en) | 1999-02-11 | 2001-09-04 | Battelle Memorial Institute | Power supply |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
JP4771661B2 (ja) | 2001-11-26 | 2011-09-14 | トラスティーズ オブ タフツ カレッジ | Post−プロリン開裂酵素の擬ペプチド性阻害剤 |
WO2003045228A2 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
EP1499336A4 (en) | 2002-04-30 | 2005-06-01 | Tufts College | PROTEASE INHIBITORS |
AU2003265264A1 (en) | 2002-07-09 | 2004-01-23 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
CN102174102A (zh) | 2003-05-15 | 2011-09-07 | 塔夫茨大学信托人 | 肽和多肽药物的稳定类似物 |
BRPI0507972A (pt) | 2004-02-23 | 2007-07-24 | Tufts College | composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada |
US20060063719A1 (en) | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
AU2006246719A1 (en) * | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
KR20080030079A (ko) * | 2005-07-05 | 2008-04-03 | 트러스티즈 오브 터프츠 칼리지 | 섬유아세포 활성 단백질 알파의 억제제 |
AU2006201635A1 (en) * | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
CN101379069A (zh) * | 2005-12-19 | 2009-03-04 | 塔夫茨大学信托人 | 软蛋白酶抑制剂及其前软形式 |
WO2008005266A2 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
WO2008116053A2 (en) * | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Fap-activated chemotherapeutic compounds, and methods of use thereof |
US20100105753A1 (en) * | 2007-03-20 | 2010-04-29 | Trustees Of Tufts College | Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof |
WO2009006473A2 (en) * | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
GEP20125599B (en) * | 2007-08-06 | 2012-08-10 | Millennium Pharm Inc | Proteasome inhibitors |
US20110112069A1 (en) * | 2007-08-17 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
WO2009111470A2 (en) * | 2008-03-03 | 2009-09-11 | Kansas State University Research Foundation | Protease assay |
JP5801585B2 (ja) | 2011-03-30 | 2015-10-28 | 株式会社ケーヒン | 燃料噴射制御システム |
EP2753334B1 (en) | 2011-08-30 | 2022-10-19 | Trustees Of Tufts College | Fap-activated proteasome inhibitors for treating solid tumors |
-
2012
- 2012-08-30 EP EP12827686.2A patent/EP2753334B1/en active Active
- 2012-08-30 CN CN201280052940.4A patent/CN103945856A/zh active Pending
- 2012-08-30 EP EP22201696.6A patent/EP4144354A1/en active Pending
- 2012-08-30 AU AU2012301810A patent/AU2012301810B2/en active Active
- 2012-08-30 ES ES12827686T patent/ES2929179T3/es active Active
- 2012-08-30 DK DK12827686.2T patent/DK2753334T3/da active
- 2012-08-30 CN CN201810059355.6A patent/CN108383893A/zh active Pending
- 2012-08-30 SI SI201232012T patent/SI2753334T1/sl unknown
- 2012-08-30 US US14/241,666 patent/US9597410B2/en active Active
- 2012-08-30 PL PL12827686.2T patent/PL2753334T3/pl unknown
- 2012-08-30 WO PCT/US2012/053140 patent/WO2013033396A2/en active Application Filing
- 2012-08-30 HU HUE12827686A patent/HUE060305T2/hu unknown
- 2012-08-30 PT PT128276862T patent/PT2753334T/pt unknown
- 2012-08-30 CA CA2846852A patent/CA2846852C/en active Active
- 2012-08-30 HR HRP20221320TT patent/HRP20221320T1/hr unknown
- 2012-08-30 JP JP2014528600A patent/JP6207509B2/ja active Active
-
2016
- 2016-05-27 US US15/167,109 patent/US9956297B2/en active Active
-
2017
- 2017-06-19 AU AU2017204121A patent/AU2017204121A1/en not_active Abandoned
- 2017-09-05 JP JP2017170106A patent/JP2018016629A/ja active Pending
-
2018
- 2018-04-13 US US15/952,648 patent/US10517955B2/en active Active
-
2019
- 2019-11-19 US US16/688,574 patent/US11065339B2/en active Active
-
2021
- 2021-06-15 US US17/348,043 patent/US20210379190A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017204121A1 (en) | 2017-07-06 |
PT2753334T (pt) | 2022-11-03 |
PL2753334T3 (pl) | 2022-12-12 |
US20140255300A1 (en) | 2014-09-11 |
US11065339B2 (en) | 2021-07-20 |
EP2753334A4 (en) | 2015-07-01 |
AU2012301810A1 (en) | 2014-04-10 |
US9956297B2 (en) | 2018-05-01 |
EP4144354A1 (en) | 2023-03-08 |
WO2013033396A2 (en) | 2013-03-07 |
JP2014527070A (ja) | 2014-10-09 |
CA2846852C (en) | 2021-01-12 |
US9597410B2 (en) | 2017-03-21 |
DK2753334T3 (da) | 2022-11-07 |
JP2018016629A (ja) | 2018-02-01 |
HUE060305T2 (hu) | 2023-02-28 |
US20190054181A1 (en) | 2019-02-21 |
CN103945856A (zh) | 2014-07-23 |
US20160346401A1 (en) | 2016-12-01 |
US10517955B2 (en) | 2019-12-31 |
HRP20221320T1 (hr) | 2023-01-06 |
JP6207509B2 (ja) | 2017-10-04 |
AU2012301810B2 (en) | 2017-06-01 |
US20200323994A1 (en) | 2020-10-15 |
EP2753334B1 (en) | 2022-10-19 |
US20210379190A1 (en) | 2021-12-09 |
WO2013033396A3 (en) | 2014-05-08 |
CN108383893A (zh) | 2018-08-10 |
EP2753334A2 (en) | 2014-07-16 |
ES2929179T3 (es) | 2022-11-25 |
CA2846852A1 (en) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2753334T (pt) | Inibidores de proteassoma ativados por fap utilizados para o tratamento de tumores sólidos | |
IL232128B (en) | Tor kinase inhibitors for cancer treatment | |
EP2558109A4 (en) | METHOD FOR TREATING HARD TUMORS | |
EP2683693A4 (en) | ROR-GAMMA-T INHIBITORS | |
EP2707719A4 (en) | DEVICE FOR DETECTING TUMOR CELLS | |
ZA201401622B (en) | Method for treating gastrointestinal stromal tumors | |
EP2706852A4 (en) | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | |
EP2770987A4 (en) | NEW CONNECTIONS AS ERK HEMMER | |
EP2785183A4 (en) | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | |
AP3529A (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors | |
EP2635286A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
ZA201208219B (en) | Method for treating wasterwater | |
IL228644A0 (en) | Cancer treatment methods | |
IL228908A0 (en) | A method for treating advanced solid tumors | |
HK1202297A1 (en) | Methods for treating acne | |
SG10201502566SA (en) | Use of novel pan-cdk inhibitors for treating tumors | |
EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
HK1174539A1 (en) | Met inhibitors for enhancing radiotherapy efficacy met | |
EP2768512A4 (en) | ENZYME HAMMER FOR CANCER TREATMENT | |
LT2519231T (lt) | Proteosomų inhibitoriai vėžio gydymui | |
HK1209040A1 (en) | Methods for treating vestibulotoxicity | |
PL2489606T3 (pl) | Płytka do przytrzymywania przedmiotów | |
GB2491461B (en) | Improved access apparatus | |
PL2497533T3 (pl) | Urządzenie do leczenia cellulitu | |
ZA201308697B (en) | Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors |